Compare · ABBV vs MURF
ABBV vs MURF
Side-by-side comparison of AbbVie Inc. (ABBV) and Murphy Canyon Acquisition Corp. (MURF): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and MURF operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV carries a market cap of $406.38B.
- ABBV has hit the wire 14 times in the past 4 weeks while MURF has been quiet.
- ABBV has more recent analyst coverage (25 ratings vs 0 for MURF).
- Company
- AbbVie Inc.
- Murphy Canyon Acquisition Corp.
- Price
- $234.88+2.11%
- $17.48-1.52%
- Market cap
- $406.38B
- -
- 1M return
- +9.46%
- -
- 1Y return
- +27.86%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2022
- News (4w)
- 14
- 0
- Recent ratings
- 25
- 0
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Murphy Canyon Acquisition Corp.
Murphy Canyon Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on identifying businesses in the real estate industry, including construction, homebuilding, real estate owners and operators, arrangers of financing, insurance, and other services for real estate, and adjacent businesses and technologies targeting the real estate space. The company was incorporated in 2021 and is based in San Diego, California.
Latest ABBV
- Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
- AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection
- AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
- AbbVie Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
- AbbVie Declares Quarterly Dividend
- Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower
- Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance
- FDA Approval for SKYRIZI issued to ABBVIE INC
- FDA Approval for SKYRIZI issued to ABBVIE INC
Latest MURF
- SEC Form SC 13G/A filed by Murphy Canyon Acquisition Corp. (Amendment)
- SEC Form SC 13G/A filed by Murphy Canyon Acquisition Corp. (Amendment)
- SEC Form SC 13G/A filed by Murphy Canyon Acquisition Corp. (Amendment)
- SEC Form S-8 filed by Murphy Canyon Acquisition Corp.
- SEC Form 424B3 filed by Murphy Canyon Acquisition Corp.
- SEC Form EFFECT filed by Murphy Canyon Acquisition Corp.
- SEC Form 4 filed by Lewis-Hall Freda C
- SEC Form 4 filed by Mcnealey Jennifer Isacoff
- SEC Form 4 filed by Bligh James
- SEC Form 4 filed by Farley Chele Chiavacci